-

2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering.

This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market.

Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets.

Business Questions:

  • How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer?
  • Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward?
  • What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?
  • Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity?
  • If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitor?
  • Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC?
  • Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?
  • How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent?
  • If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC?
  • What are KOLs' opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed?

For more information about this newsletter visit https://www.researchandmarkets.com/r/9ke1kl

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Industry:

Research and Markets

Release Versions
English

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

United States Semaglutide Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, Eli Lilly and Co, AstraZeneca, Biocon, Johnson and Johnson, Pfizer, AbbVie, and Sanofi - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "United States Semaglutide Market Report by Product, Application, Distribution Channel, States and Company Analysis, 2025-2033" report has been added to ResearchAndMarkets.com's offering. United States Semaglutide Market is expected to expand from US$ 8.17 Billion in 2024 to US$ 17.29 Billion in 2033 at a Compound Annual Growth Rate (CAGR) of 8.68% during 2025-2033 The growth is fueled by rising awareness regarding obesity control, increasing incidence of diabetes,...

GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: Growing Shift of Weekly Injectables Toward Orals and Multi-Agonists - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, Tirzepatide), Type (Patented, Biosimilars), Format (Single Dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% The report will help market leaders/new...

Liraglutide and Semaglutide Global Strategic Business Analysis Report 2025-2030: Regulatory Pipeline for Pediatric and Adolescents With Obesity Creates Long-Term Market Opportunities - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Liraglutide and Semaglutide - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Liraglutide and Semaglutide was valued at US$17.1 Billion in 2024 and is projected to reach US$29.8 Billion by 2030, growing at a CAGR of 9.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Liraglutide and s...
Back to Newsroom